Gluz O, Kuemmel S, Nitz U, Braun M, et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol 2023 Apr 14:S0923-7534(23)00136-9. doi: 10.1016/j.annonc.2023.
PMID: 37062416